Press Releases
Press Releases
Events
June 2026
Evon Medics Enters a New Era as Evon Medics, Inc.
Evon Medics is proud to announce the successful completion of its incorporation and the official transition from Evon Medics LLC to Evon Medics, Inc. This milestone represents an important step in the company’s evolution as a neuroscience research and medical device innovator dedicated to advancing brain health and transforming patient outcomes. While our legal structure and corporate name have changed, our commitment to pioneering research, cutting-edge technology, and scientific excellence remains unchanged. As Evon Medics, Inc., we are better positioned to expand our impact, accelerate innovation, strengthen strategic partnerships, and continue developing solutions that advance the future of neuroscience and healthcare.
April 2026
NIH Recognizes COAT™ Study, Highlighting Breakthrough in Alzheimer’s Research
Evon Medics Inc. is pleased to announce that its research on the Computerized Olfactory Adaptive Training (COAT™) system has been recognized by the National Institutes of Health (NIH), marking a major milestone in Alzheimer’s research. The NIH-featured study shows that a six-month COAT™ intervention is linked to improved cognition and increased gray matter in key memory-related brain regions. These findings highlight COAT’s potential as a non-invasive, home-based solution for early intervention in cognitive decline.
March 2026
New Study Highlights Promising Impact of COAT Technology on Early Alzheimer’s Intervention
Evon Medics Inc. announces the publication of a new clinical study highlighting the potential of its Computerized Olfactory Adaptive Training (COAT™) system in improving cognition and slowing early brain changes linked to Alzheimer’s disease. Conducted in individuals with mild cognitive impairment (MCI), the study found that COAT™ users experienced measurable cognitive improvements and positive changes in key memory-related brain regions. These findings reinforce Evon Medics’ commitment to developing innovative, non-invasive solutions for early neurological intervention.
February 2026
Evon Medics Inc. Launches MemoryDriver™, a Breakthrough Brain Training Solution
Evon Medics Inc. is pleased to announce the official launch of MemoryDriver™, an innovative brain training application designed to support cognitive performance, mental clarity, and long-term brain health. MemoryDriver™ combines scientifically informed exercises with an intuitive, user-friendly experience to help users strengthen memory, focus, and mental agility through consistent practice. Developed with everyday users in mind, making cognitive training both engaging and accessible.
October 2025
Evon Medics’ Team Participates in BluePrint MedTech Seedling Bootcamp in Washington, D.C.
Staff members from Evon Medics Inc. recently attended the BluePrint MedTech Seedling Bootcamp held at the Kellogg Conference Center in Washington, D.C. . The intensive program brought together innovators, researchers, and industry leaders focused on accelerating the next generation of neurotechnology solutions. During the bootcamp, participants engaged in sessions centered on advancing MedTech innovation, gaining valuable insights into the development, commercialization, and scaling of neurotechnology products.
February 2024
NIH SEED Spotlights Dr. Evaristus Nwulia and Evon Medics Inc. During Black History Month
Evon medics Inc. Co-Founder and Chief Scientific Officer, Dr. Evaristus Nwulia, was recognized by the National Institutes of Health (NIH) SEED Office during Black History Month for his pioneering contributions to neuroscience and medical innovation. The NIH SEED spotlight celebrated Dr. Nwulia’s leadership in advancing research and developing breakthrough medical technologies aimed at combating devastating neurological diseases, including Alzheimer’s disease. This recognition highlights Evon Medics’ unwavering commitment to translating cutting-edge scientific discoveries into transformative healthcare solutions that improve cognitive health and enhance patients’ quality of life.
September 2022
Evon Medics, Inc. Co-Founder Appointed Director/Principal Investigator NeuroTech Harbor Technology Accelerator
Evon Medics, Inc. Co-Founder, Dr. Evaristus Nwulia, has been appointed as the Director of the Seedlings Program and Lead Principal Investigator at the NeuroTech Harbor (NTH) Technology Accelerator. The NeuroTech Harbor is supported by a grant from the National Institutes of Health (NIH) Blueprint MedTech program.
May 2022
National Institute on Drug Abuse issues $2.8m SBIR Fasttrack Financial Award to Evon Medics Inc.
The National Institute on Drug Abuse apart of the National Institutes of Health issued Small Business Innovation Research (SBIR) Fasttrack award of $2.8m to Evon Medics Inc. for the Development and Evaluation of its mobile health platform for remote management of substance use disorders (SUD). This study will address the healthcare needs of communities of socially disadvantaged populations that lag in the adoption of mobile platforms due to the inability to read, digital illiteracy, lack of access to smartphones, absence of reliable Wi-Fi or internet, and financial constraints.
June 2021
George C. McFarland, MSW Joins Evon Medics Inc. as Advisor
Mr. George McFarland joins the Evon Medics Inc Advisory Board effective June 1, 2021. George brings his wealth of experience managing over $100 million in grants and contracts to promote health and human development. His network and experience working with numerous organizations throughout the United States to improve the quality of life in communities affected by health and socially determined risks would also be valuable to Evon Medics Inc. as we continue to engage these underserved populations in our clinical trials.
April 2021
National Institute on Aging issues $2.5m SBIR Phase II Financial Award to Evon Medics Inc.
The National Institute on Aging a part of the National Institutes of Health issued the Small Business Innovation Research (SBIR) Phase II award of $2.5m to Evon Medics Inc. for the Development and Evaluation of its Computerized Olfactory Adaptive Training (COAT™) for the treatment of Alzheimer’s Disease. This is following encouraging results from the successful SBIR Phase I study.
September 2020
National Institute on Drug Abuse issues $1.7m SBIR Phase II Financial Award to Evon Medics Inc.
The National Institute on Drug Abuse a part of the National Institutes of Health issued Small Business Innovation Research (SBIR) Phase II award of $1.7m to Evon Medics Inc. for the Development and Evaluation of its Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) for the treatment of Opioid Use Disorder. This is following a hugely successful SBIR Phase I study.
March 2020
Evon Medics Inc. completes successful Phase I clinical trials
March 2020, Evon Medics Inc completes successful Phase I clinical trials for its Computerized Olfactory Adaptive Training Program (COAT™), developed for preventing the development and progression of Alzheimer’s Disease (AD) and its Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT), developed for the management of the Opioid Use Disorder (OUD). Both solutions are home-based and user-friendly neuromodulatory devices.
October 2018
National Institute on Aging Issues SBIR Financial Award to Evon Medics Inc
The National Institute on Aging at the National Institutes of Health issued Small Business Innovation Research (SBIR) award to Evon Medics Inc. to support the development and evaluation of its computerized olfactory training program (COT) for cognitive decline in preclinical and early Alzheimer’s Disease (AD). COT is a key differentiating feature of the olfactory treatment delivery system (OTDS) platform developed by EvON Medics for the treatment of a variety of brain conditions.
July 2026
Dr. Evaristus Nwulia Presents COAT™ Research at AAIC 2026
Dr. Evaristus Nwulia, Co-Founder and Chief Scientific Officer of Evon Medics, presented the latest clinical findings on the Closed-Loop Olfactory and Auditory Treatment (COAT™) platform at the Alzheimer’s Association International Conference (AAIC 2026) in London. The presentation highlighted Evon Medics’ pioneering research in non-invasive neuromodulation and reinforced the company’s commitment to advancing innovative, science-driven solutions for Alzheimer’s disease and other neurodegenerative disorders on the global stage.
May 2026
Evon Medics Inc. Team Showcases COAT™ and MemoryDriver™ at Amplify MedTech Startup Showcase
Evon Medics Inc. team members Vamsi Reddy, Jamal, and Dylan presented the company’s innovative COAT™ platform and MemoryDriver™
cognitive assessment solution at the Amplify MedTech Startup Showcase. The event provided an opportunity to demonstrate Evon Medics’ cutting-edge technologies to healthcare innovators, investors, and industry leaders, reinforcing the company’s mission to advance neuroscience through clinically driven, non-invasive solutions for cognitive health.
cognitive assessment solution at the Amplify MedTech Startup Showcase. The event provided an opportunity to demonstrate Evon Medics’ cutting-edge technologies to healthcare innovators, investors, and industry leaders, reinforcing the company’s mission to advance neuroscience through clinically driven, non-invasive solutions for cognitive health.
April 2026
Vamsi Reddy Speaks on Building Global HealthTech Products at HealthXAfrica
Vamsi Reddy, Global Head of Product Development, Evon Medics Inc. delivered a presentation at HealthXAfrica on the journey of building globally impactful health technology products. Drawing on Evon Medics’ experience in developing innovative neuroscience solutions, the session explored the challenges and opportunities in translating scientific innovation into scalable medical technologies, while highlighting the importance of collaboration, clinical validation, and patient-centered design in advancing healthcare worldwide.
February 2026
Evon Medics Inc. Launches MemoryDriver™ 1.0
Evon Medics Inc. officially launched MemoryDriver™ 1.0, an innovative digital cognitive assessment platform designed to support the early detection and monitoring of memory and spatial navigation changes. The launch marked an important milestone in the company’s mission to develop accessible, science-driven tools that empower clinicians, researchers, and individuals with advanced solutions for cognitive health and neurodegenerative disease assessment.
December 2025
Charles Nwaokobia Represents Evon Medics Inc. at The MedTech Conference Powered by AdvaMed
Charles Nwaokobia, COO & President of Evon Medics, represented the company at The MedTech Conference, powered by AdvaMed. As part of the global gathering of medical technology leaders, Charles showcased Evon Medics’ vision for advancing neuroscience through innovative medical devices, engaged with industry stakeholders, and explored strategic partnerships to accelerate the commercialization and global impact of the company’s breakthrough technologies.